AIM
CLDX icon

Advantage Investment Management’s Celldex Therapeutics CLDX Stock Holding History

Advantage Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$0 Hold
114
– – ﹤0.01% 916
2019
Q2 		$0 Hold
114
– – ﹤0.01% 930
2019
Q1 		$1K Sell
114
-1
-0.9% -$5 ﹤0.01% 887
2018
Q4 		$0 Hold
115
– – ﹤0.01% 993
2018
Q3 		$1K Hold
115
– – ﹤0.01% 965
2018
Q2 		$1K Hold
115
– – ﹤0.01% 898
2018
Q1 		$4K Hold
115
– – ﹤0.01% 827
2017
Q4 		$5K Buy
115
+82
+248% +$3.51K ﹤0.01% 813
2017
Q3 		$1K Hold
33
– – ﹤0.01% 975
2017
Q2 		$1K Hold
33
– – ﹤0.01% 1008
2017
Q1 		$2K Hold
33
– – ﹤0.01% 892
2016
Q4 		$2K Sell
33
-462
-93% -$26.3K ﹤0.01% 840
2016
Q3 		$30K Buy
495
+44
+10% +$2.74K 0.01% 433
2016
Q2 		$30K Buy
451
+50
+12% +$3.17K 0.01% 420
2016
Q1 		$23K Buy
401
+18
+5% +$2.02K 0.01% 438
2015
Q4 		$90K Buy
383
+18
+5% +$3.92K 0.05% 247
2015
Q3 		$58K Hold
365
– – 0.03% 291
2015
Q2 		$138K Sell
365
-15
-4% -$5.96K 0.07% 186
2015
Q1 		$159K Buy
380
+51
+16% +$18.2K 0.09% 165
2014
Q4 		$90K Buy
+329
New +$81.8K 0.07% 227

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advantage Investment Management's CLDX Position: Q3 2019 in Review

Advantage Investment Management held its Celldex Therapeutics (CLDX) position steady in Q3 2019 at 114 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #916.

Advantage Investment Management first reported a position in CLDX in Q4 2014 and has held it in 20 quarters since. The position peaked at $159K in Q1 2015. 54 funds tracked by Wall St. Rank hold CLDX as of Q3 2019.

  • Advantage Investment Management held 114 shares of Celldex Therapeutics worth $0 as of Q3 2019.
  • Advantage Investment Management left its Celldex Therapeutics share count unchanged in Q3 2019.
  • Celldex Therapeutics made up ﹤0.01% of Advantage Investment Management's portfolio in Q3 2019, its #916 holding.
  • Advantage Investment Management first reported a position in Celldex Therapeutics in Q4 2014 and has held it in 20 quarters since.
  • Advantage Investment Management's Celldex Therapeutics position peaked at $159K in Q1 2015.
  • 54 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.